Please check your internet connection and try again.
# Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a brand name for a combination product containing sofosbuvir and velpatasvir. It is a direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus (HCV) infection.
## Primary Indications
Chronic Hepatitis C Virus (HCV) infection. Specifically, it is indicated for genotypes 1, 2, 3, 4, 5, and 6.
## Adult Dosing
**Recommended dose:** One tablet (sofosbuvir 400 mg / velpatasvir 100 mg) taken orally once daily.
**Duration of treatment:** Typically 12 weeks, but may be shorter (e.g., 8 weeks) for treatment-naive patients with genotype 1 or 3 HCV without cirrhosis. Consult specific guidelines for duration.
## Pediatric Dosing
Use in pediatric patients has not been established.
## Dose Adjustments
No dose adjustment is required for renal impairment.
For patients with moderate to severe hepatic impairment, caution is advised, and it is generally not recommended. Specific recommendations depend on the degree of impairment.
## Contraindications
Hypersensitivity to sofosbuvir, velpatasvir, or any component of the formulation.
Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort).
## Adverse Effects
Common adverse effects include headache, fatigue, nausea, insomnia, and anemia.
## Key Drug Interactions
* **Strong P-gp inducers:** Concurrent use with strong P-gp inducers significantly reduces plasma concentrations of velpatasvir, rendering the combination ineffective. Avoid coadministration.
* **Antacids, H2 receptor antagonists, proton pump inhibitors:** May decrease velpatasvir exposure. Separate administration by at least 4 hours (PPIs), 12 hours (H2 blockers), or 12 hours before and 4 hours after (antacids).
## Monitoring
* HCV RNA levels to assess viral response.
* Liver function tests.
* Renal function.
* Consider baseline and on-treatment assessment for potential psychiatric effects.
## Clinical Pearls
* This medication is part of a curative regimen for HCV and is often used in combination with ribavirin or other DAAs depending on the genotype, prior treatment history, and presence of cirrhosis.
* It is crucial to confirm the specific HCV genotype before initiating treatment.
* Ensure patients are counseled on the importance of adherence to achieve sustained virologic response (SVR).
* Hepatitis B virus (HBV) coinfection should be screened for and managed appropriately, as DAAs can lead to HBV reactivation.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace current prescribing information or clinical judgment. Always verify the most up-to-date prescribing information with the manufacturer's official product literature and relevant clinical guidelines.
